Search

Your search keyword '"therapy related myeloid neoplasms"' showing total 3 results
Start Over Descriptor "therapy related myeloid neoplasms"
3 results on '"therapy related myeloid neoplasms"'

1. Outcomes of patients with therapy‐related myeloid neoplasms after treatment with poly(ADP‐ribose) polymerase proteins inhibitors for solid tumours.

Author

Almanza‐Huante, Emmanuel, Bataller, Alex, Urrutia, Samuel, Gener‐Ricos, Georgina, Briski, Robert Edward, Kanagal‐Shamanna, Rashmi, Lu, Karen H., Westin, Shannon N., Yap, Timothy A., Takahashi, Koichi, Ravandi, Farhad, Alvarado, Yesid, Kadia, Tapan, Sasaki, Koiji, Kantarjian, Hagop M., and Garcia‐Manero, Guillermo

Subjects
*POLY ADP ribose, *ACUTE promyelocytic leukemia, *TREATMENT effectiveness, *TUMORS, *BRCA genes, *ACUTE myeloid leukemia, *HEREDITARY cancer syndromes
Abstract

Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights. Keywords: PARP inhibitors; therapy related myeloid neoplasms; therapy-related acute myeloid leukaemia; therapy-related myelodysplastic syndrome EN PARP inhibitors therapy related myeloid neoplasms therapy-related acute myeloid leukaemia therapy-related myelodysplastic syndrome e25 e29 5 04/20/23 20230501 NES 230501 Therapy-related myeloid neoplasms represent 10%-20% of all newly diagnosed myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).[1] These disorders are frequently associated with high-risk genetic features. Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours Therapy related myeloid neoplasms, PARP inhibitors, therapy-related myelodysplastic syndrome, therapy-related acute myeloid leukaemia. [Extracted from the article]

Published
2023
Full Text
View/download PDF

2. Outcome of therapy-related myeloid neoplasms treated with azacitidine

Author

Fianchi Luana, Criscuolo Marianna, Lunghi Monia, Gaidano Gianluca, Breccia Massimo, Levis Alessandro, Finelli Carlo, Santini Valeria, Musto Pellegrino, Oliva Esther N, Leoni Pietro, Spiriti Antonietta, D’Alò Francesco, Hohaus Stefan, Pagano Livio, Leone Giuseppe, and Voso Maria

Subjects
Therapy related myeloid neoplasms, Hypomethylating agents, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Therapy-related myeloid neoplasms (t-MN), including myelodysplastic syndromes and acute myeloid leukemia (t-MDS and t-AML) are associated to clinical and biologic unfavorable prognostic features, including high levels of DNA methylation. Methods We retrospectively evaluated 50 t-MN patients (34 MDS and 16 AML) selected among all patients receiving azacitidine (AZA) at 10 Italian Hematology Centers. Patients had developed a t-MN at a median of 6.5 years (range 1.7- 29) after treatment of the primary tumor (hematological neoplasm, 27 patients; solid tumor, 23 patients). Results The overall response rate was 42% (complete remission: 10 patients, partial remission: 2 and hematological improvement: 8 patients) and was obtained after a median of 3 cycles (range 1–6). Median overall survival (OS) was 21 months (range 1–53.6+) from AZA start. OS was significantly better in patients with less than 20% blasts, in normal karyotype t-AML and when AZA was used as front-line treatment. This was confirmed by the multivariate analysis. Conclusions This study reports efficacy of AZA in the largest series of therapy-related MN patients treated with 5-AZA. Our data show that blasts and karyotype maintain their important prognostic role in t-MN also in the azacitidine era.

Published
2012
Full Text
View/download PDF

3. Outcome of therapy-related myeloid neoplasms treated with azacitidine

Author

Pellegrino Musto, Francesco D'Alo', Alessandro Levis, Carlo Finelli, Massimo Breccia, Antonietta Aloe Spiriti, Maria Teresa Voso, Gianluca Gaidano, Monia Lunghi, Luana Fianchi, Giuseppe Leone, Stefan Hohaus, Pietro Leoni, Livio Pagano, Esther Oliva, Valeria Santini, and Marianna Criscuolo

Subjects
Oncology, Myeloid, Male, Cancer Research, Antimetabolites, hemic and lymphatic diseases, Neoplasms, 80 and over, Aged, 80 and over, Leukemia, Remission Induction, Myeloid leukemia, Neoplasms, Second Primary, Hematology, lcsh:Diseases of the blood and blood-forming organs, hypomethylating agents, therapy related myeloid neoplasms, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Prognosis, Primary tumor, Antineoplastic, Survival Rate, Leukemia, Myeloid, Acute, medicine.anatomical_structure, Second Primary, Azacitidine, Female, Therapy related myeloid neoplasms, medicine.drug, Adult, medicine.medical_specialty, Antimetabolites, Antineoplastic, Hypomethylating agents, Acute, lcsh:RC254-282, Internal medicine, medicine, Humans, Survival rate, Molecular Biology, Aged, Retrospective Studies, DNA Methylation, Myelodysplastic Syndromes, business.industry, lcsh:RC633-647.5, Myelodysplastic syndromes, Research, therapy-related, medicine.disease, secondary MDS, therapy, Immunology, Hematological neoplasm, business, Settore MED/15 - Malattie del Sangue
Abstract

Background Therapy-related myeloid neoplasms (t-MN), including myelodysplastic syndromes and acute myeloid leukemia (t-MDS and t-AML) are associated to clinical and biologic unfavorable prognostic features, including high levels of DNA methylation. Methods We retrospectively evaluated 50 t-MN patients (34 MDS and 16 AML) selected among all patients receiving azacitidine (AZA) at 10 Italian Hematology Centers. Patients had developed a t-MN at a median of 6.5 years (range 1.7- 29) after treatment of the primary tumor (hematological neoplasm, 27 patients; solid tumor, 23 patients). Results The overall response rate was 42% (complete remission: 10 patients, partial remission: 2 and hematological improvement: 8 patients) and was obtained after a median of 3 cycles (range 1–6). Median overall survival (OS) was 21 months (range 1–53.6+) from AZA start. OS was significantly better in patients with less than 20% blasts, in normal karyotype t-AML and when AZA was used as front-line treatment. This was confirmed by the multivariate analysis. Conclusions This study reports efficacy of AZA in the largest series of therapy-related MN patients treated with 5-AZA. Our data show that blasts and karyotype maintain their important prognostic role in t-MN also in the azacitidine era.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results